When rifampin lowers levels of lopinavir/ritonavir, what substitution may be considered?

• A. Increase the dose of lopinavir/ritonavir
• B. Stop protease inhibitor therapy
• C. Substitute rifabutin and adjust anti-retroviral therapy
• D. Use azithromycin instead

Answer: (C)

Rifampin dramatically speeds up the metabolism of many antiretrovirals by inducing enzymes (mainly CYP3A4) and transporters, which can drop the levels of a boosted protease inhibitor like lopinavir/ritonavir well below therapeutic. When a patient on lopinavir/ritonavir needs TB treatment, this interaction can undermine HIV control.

Substituting rifampin with rifabutin is a common approach because rifabutin is a rifamycin with weaker inducing effects. However, rifabutin itself is still an inducer and is affected by ritonavir, so the anti-retroviral regimen must be adjusted to maintain effective HIV therapy. In practice, this often means using a reduced rifabutin dose and altering how frequently it’s given when combined with ritonavir-boosted lopinavir (for example, rifabutin given every other day or a few times per week, rather than daily). This substitution preserves TB treatment while keeping HIV drug levels in the therapeutic range.

Choosing this route is preferred over simply increasing the lopinavir/ritonavir dose, which won’t reliably overcome the strong induction by rifampin. It’s also not appropriate to stop protease inhibitor therapy or to rely on antibiotics like azithromycin to manage TB, since those options don’t provide effective TB treatment and wouldn’t address the interaction issue.

So, substituting rifabutin and adjusting the anti-retroviral regimen is the balanced approach to maintain both TB and HIV therapy effectiveness when rifampin would otherwise lower lopinavir/ritonavir levels.